Advertisement

Antifungal

Cidara’s Anti-Fungal Receives Approval with Priority Review from US FDA

March 23rd, 2023|Categories: Featured, Industry News|Tags: , , , |

Rezzayo, Cidara Therapeutics’ newest anti-fungal drug, has received the nod from the US Food and Drug Administration (FDA) for approval under priority review for two kinds of candida infections, candidemia and invasive candidiasis. The drug is currently being reviewed by the EMA, which has already granted its marketing authorization approval.

Go to Top